Home Featured

Featured

Random

Terran Biosciences announces publication of four PCT patent applications covering breakthroughs in novel empathogens, including improved versions of methylone, ethylone, MDEA, MDAI, and MBDB

Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product

PTSF47 – Covid, Ketamine, and Human Rights

NeonMind Announces Divestiture of Consumer Related and Other Non-Core Assets

MYDECINE INNOVATIONS GROUP ANNOUNCES CLOSING UNDER SHARE SUBSCRIPTION AGREEMENT

MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2022

Silo Pharma extends research pact for Alzheimer’s and Stress Induced Anxiety...

Lobe Sciences Appoints NFL Alumni Association President, Bart Oates Esq. to...

Psychedelics Weekly – Proposition 122 in Action, The Economics of Psychedelics,...

Nova Mentis Autism Clinical Study Approved by Canadian Institutional Review Board

Clinical Director of Imperial College’s Center for Psychedelic Research Joins Entheon...

Field Trip Health Announces $50 Million Bought Deal Offering of Common...

Pα+ Psychedelic Patent Analysis (November 2023)

MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC

2025 Year in Review: 10 Standout Stories in Psychedelics

2025 Year in Review: Looking Ahead to Psychedelics in 2026 (Video)

Oli Genn-Bash: Functional Mushrooms, Hype Cycles, and Mycelial Thinking

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.